Abstract
Pharmacogenomic testing has a guideline base, a falling unit cost and, since 2023, one large multinational trial behind it. What it lacks is a routine delivery route. This narrative review examines the evidence that pharmacists can supply that route, drawing on implementation studies, randomised trials, economic evaluations and scoping reviews identified by structured searching in November 2026. Actionable genotypes are close to universal: 91% of 9,589 patients in one preemptive programme carried at least one, and modelling from Dutch and United Kingdom dispensing data places an actionable drug-gene interaction at 19.1-23.6% of first prescriptions for the drugs concerned. Pharmacist-led services have been shown to be feasible in hospitals, community pharmacies and primary care, with prescribers accepting 70.5-91.8% of recommendations in the better-documented programmes. Outcome evidence is thinner. The PREPARE trial (n = 6,944) reported an odds ratio of 0.70 for clinically relevant adverse drug reactions, yet the same reduction appeared in participants with no actionable result, which weakens a causal reading. Two small randomised trials of pharmacist-delivered testing against an untested comparator favour the intervention; both are open to bias from unblinded assessment, commercial involvement or short follow-up. The studies were too heterogeneous in design and endpoint to pool. The pathway loses most of its value at two points outside the pharmacist's direct control: transfer of the recommendation to the prescriber and durable recording of the result. Economic evidence supports single drug-gene tests more firmly than pharmacist-delivered panels. Routine adoption now depends on reimbursed consultation time, shared records with decision support, and a blinded, individually randomised trial of the pharmacist-led model.